BidaskClub lowered shares of Agenus (NASDAQ:AGEN) from a sell rating to a strong sell rating in a research note published on Saturday.
A number of other analysts have also recently commented on AGEN. Zacks Investment Research cut Agenus from a hold rating to a sell rating in a research report on Tuesday, March 20th. ValuEngine cut Agenus from a sell rating to a strong sell rating in a research report on Friday, December 29th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. Agenus presently has an average rating of Hold and an average price target of $5.81.
Agenus stock opened at $4.46 on Friday. The company has a debt-to-equity ratio of -1.88, a current ratio of 1.30 and a quick ratio of 1.30. Agenus has a one year low of $3.20 and a one year high of $6.19.
Institutional investors and hedge funds have recently modified their holdings of the business. MetLife Investment Advisors LLC purchased a new stake in Agenus in the fourth quarter worth about $124,000. Raymond James & Associates purchased a new stake in Agenus in the fourth quarter worth about $130,000. Cubist Systematic Strategies LLC purchased a new stake in Agenus in the third quarter worth about $134,000. North Star Asset Management Inc. purchased a new stake in Agenus in the fourth quarter worth about $222,000. Finally, Highbridge Capital Management LLC increased its position in Agenus by 242.8% in the third quarter. Highbridge Capital Management LLC now owns 56,642 shares of the biotechnology company’s stock worth $249,000 after buying an additional 40,118 shares in the last quarter. Institutional investors and hedge funds own 36.46% of the company’s stock.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.